Zacks: Analysts Expect Abbott Laboratories (ABT) Will Announce Earnings of $0.61 Per Share

Share on StockTwits

Wall Street brokerages expect Abbott Laboratories (NYSE:ABT) to announce earnings per share of $0.61 for the current quarter, according to Zacks. Seven analysts have made estimates for Abbott Laboratories’ earnings. The highest EPS estimate is $0.62 and the lowest is $0.61. Abbott Laboratories reported earnings per share of $0.59 during the same quarter last year, which would suggest a positive year over year growth rate of 3.4%. The business is expected to issue its next quarterly earnings results on Wednesday, April 17th.

On average, analysts expect that Abbott Laboratories will report full-year earnings of $3.20 per share for the current financial year, with EPS estimates ranging from $3.15 to $3.23. For the next year, analysts expect that the business will report earnings of $3.60 per share, with EPS estimates ranging from $3.55 to $3.70. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Abbott Laboratories.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, January 23rd. The healthcare product maker reported $0.81 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.81. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.82 billion. Abbott Laboratories had a net margin of 7.74% and a return on equity of 16.55%. Abbott Laboratories’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.74 EPS.

ABT has been the topic of several research analyst reports. Zacks Investment Research lowered shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, March 5th. Morgan Stanley boosted their price objective on shares of Abbott Laboratories from $82.00 to $85.00 and gave the company an “overweight” rating in a report on Wednesday, January 2nd. Goldman Sachs Group upgraded shares of Abbott Laboratories from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $78.00 to $81.00 in a report on Friday, November 30th. Citigroup lowered shares of Abbott Laboratories from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $72.00 to $68.00 in a report on Wednesday, January 2nd. Finally, Credit Suisse Group initiated coverage on shares of Abbott Laboratories in a report on Monday, December 17th. They issued an “outperform” rating and a $82.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $79.71.

In other Abbott Laboratories news, CFO Brian B. Yoor sold 2,246 shares of Abbott Laboratories stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $78.00, for a total value of $175,188.00. Following the completion of the transaction, the chief financial officer now directly owns 116,627 shares of the company’s stock, valued at approximately $9,096,906. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Roger Bird sold 9,188 shares of Abbott Laboratories stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $79.06, for a total value of $726,403.28. Following the completion of the transaction, the insider now directly owns 60,195 shares of the company’s stock, valued at $4,759,016.70. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 198,669 shares of company stock valued at $14,085,330. 0.74% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Csenge Advisory Group acquired a new position in shares of Abbott Laboratories during the third quarter worth about $31,000. 1 North Wealth Services LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth about $33,000. Brand Asset Management Group Inc. grew its position in shares of Abbott Laboratories by 66.7% during the fourth quarter. Brand Asset Management Group Inc. now owns 500 shares of the healthcare product maker’s stock worth $36,000 after buying an additional 200 shares in the last quarter. Exane Derivatives acquired a new position in shares of Abbott Laboratories during the fourth quarter worth about $42,000. Finally, Clarfeld Financial Advisors LLC acquired a new position in shares of Abbott Laboratories during the fourth quarter worth about $43,000. 74.31% of the stock is owned by institutional investors.

Shares of ABT opened at $79.86 on Tuesday. The stock has a market capitalization of $137.43 billion, a P/E ratio of 27.73, a P/E/G ratio of 2.09 and a beta of 1.13. Abbott Laboratories has a 12-month low of $56.81 and a 12-month high of $80.15. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.20 and a current ratio of 1.62.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 1.60%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s dividend payout ratio is currently 44.44%.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

Featured Article: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Abbott Laboratories (ABT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.